BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 15017723)

  • 1. [The expression of cell adhesion molecule Syndecan-1 and E-candherin in laryngeal cancer].
    Li Y; Yang C
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2003 Dec; 17(12):736-8. PubMed ID: 15017723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.
    Rintala M; Inki P; Klemi P; Jalkanen M; Grénman S
    Gynecol Oncol; 1999 Dec; 75(3):372-8. PubMed ID: 10600292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma.
    Kurokawa H; Zhang M; Matsumoto S; Yamashita Y; Tanaka T; Takamori K; Igawa K; Yoshida M; Fukuyama H; Takahashi T; Sakoda S
    J Oral Pathol Med; 2006 May; 35(5):301-6. PubMed ID: 16630294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between reduction of syndecan-1 expression and clinico-pathological parameters in squamous cell carcinoma of tongue.
    Ro Y; Muramatsu T; Shima K; Yajima Y; Shibahara T; Noma H; Shimono M
    Int J Oral Maxillofac Surg; 2006 Mar; 35(3):252-7. PubMed ID: 16280239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syndecan-1 expression has prognostic significance in head and neck carcinoma.
    Anttonen A; Kajanti M; Heikkilä P; Jalkanen M; Joensuu H
    Br J Cancer; 1999 Feb; 79(3-4):558-64. PubMed ID: 10027330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck.
    Inki P; Joensuu H; Grénman R; Klemi P; Jalkanen M
    Br J Cancer; 1994 Aug; 70(2):319-23. PubMed ID: 8054282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syndecan-1: a new prognostic marker in laryngeal cancer.
    Pulkkinen JO; Penttinen M; Jalkanen M; Klemi P; Grénman R
    Acta Otolaryngol; 1997 Mar; 117(2):312-5. PubMed ID: 9105473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma.
    Mukunyadzi P; Liu K; Hanna EY; Suen JY; Fan CY
    Mod Pathol; 2003 Aug; 16(8):796-801. PubMed ID: 12920224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas.
    Mikami S; Ohashi K; Usui Y; Nemoto T; Katsube K; Yanagishita M; Nakajima M; Nakamura K; Koike M
    Jpn J Cancer Res; 2001 Oct; 92(10):1062-73. PubMed ID: 11676857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syndecan-1 expression in laryngeal cancer.
    Klatka J
    Eur Arch Otorhinolaryngol; 2002 Mar; 259(3):115-8. PubMed ID: 12003262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prognostic value of syndecan-1 in gastric cancer.
    Wiksten JP; Lundin J; Nordling S; Kokkola A; Haglund C
    Anticancer Res; 2000; 20(6D):4905-7. PubMed ID: 11326638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of syndecan-1 expression in breast cancer.
    Leivonen M; Lundin J; Nordling S; von Boguslawski K; Haglund C
    Oncology; 2004; 67(1):11-8. PubMed ID: 15459490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syndecan-1 expression--a novel prognostic marker in pancreatic cancer.
    Juuti A; Nordling S; Lundin J; Louhimo J; Haglund C
    Oncology; 2005; 68(2-3):97-106. PubMed ID: 15886501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes.
    Inki P; Larjava H; Haapasalmi K; Miettinen HM; Grenman R; Jalkanen M
    Eur J Cell Biol; 1994 Feb; 63(1):43-51. PubMed ID: 8005104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies.
    Mitselou A; Ioachim E; Peschos D; Charalabopoulos K; Michael M; Agnantis NJ; Vougiouklakis T
    Exp Oncol; 2007 Mar; 29(1):54-60. PubMed ID: 17431390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of syndecan-1 expression in differentiated type early gastric cancer and background mucosa with gastric cellular phenotype.
    Watari J; Saitoh Y; Fujiya M; Shibata N; Tanabe H; Inaba Y; Okamoto K; Maemoto A; Ohta T; Yasuda A; Ayabe T; Ashida T; Yokota K; Obara T; Kohgo Y
    J Gastroenterol; 2004; 39(2):104-12. PubMed ID: 15069616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Is syndecan-1 an independent prognostic factor in patients with laryngeal carcinoma?].
    Klatka J; Skomra D; Paduch R; Kupisz K; Tryka E; Harytanowicz M; Kłos A
    Otolaryngol Pol; 2004; 58(5):933-40. PubMed ID: 15732779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence.
    Day RM; Hao X; Ilyas M; Daszak P; Talbot IC; Forbes A
    Virchows Arch; 1999 Feb; 434(2):121-5. PubMed ID: 10071246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression of syndecan-1 is preferentially reduced compared with that of E-cadherin in acantholytic squamous cell carcinoma.
    Bayer-Garner IB; Smoller BR
    J Cutan Pathol; 2001 Feb; 28(2):83-9. PubMed ID: 11168756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome.
    Kumar-Singh S; Jacobs W; Dhaene K; Weyn B; Bogers J; Weyler J; Van Marck E
    J Pathol; 1998 Nov; 186(3):300-5. PubMed ID: 10211120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.